BOT - Anything but charting, page-9639

In my layman's view, its because we haven't got any near term catalysts to warrant pressuring the market into mass adoption / FOMO just yet. Prior to FDA approval was certainly a far different time to take a position with BOT (albeit far more risky).

So... sure we are significantly de-risked, but sales are still a wee while away. If I had to assume, once we hear that we have started selling the product, we'll probably see the market rush a bit quicker to jump onboard before the following first quarterly report, to get in before the market's hear the news of revenue actually being received.

Not financial advice.

I'm happy to sit/wait; I don't want to fluff with CGT and buy back in later, which will see me consume my CGT discount early.

Judging by the serious lack of volume (compared to pre FDA announcement), I feel many others share the same sentiment of sit and wait, and the good things for BOT will come.